Normal tissue tolerance for high-grade gliomas: is it an issue?

Area of Science:

• Radiation oncology
• Neuro-oncology
• Clinical trial design

Background:

• Normal tissue tolerance is critical in high-grade glioma (HGG) treatment due to improved survival in young patients and hypofractionation use in elderly patients.
• Distinguishing tumor progression from treatment-induced effects is challenging, impacting endpoint evaluation.
• Evolving treatment strategies necessitate updated understanding of dose and volume parameters.

Purpose of the Study:

• To review current dose tolerance parameters for HGG radiation therapy.
• To discuss clinical, pathologic, and radiographic endpoints and their interpretation.
• To highlight the need for prospective evaluation of neurocognitive function and imaging in future HGG trials.

Main Methods:

• Literature review of dose tolerance parameters in HGG treatment.
• Analysis of clinical endpoints, including tumor-related and treatment-related effects.
• Review of relevant clinical trials focusing on dose and volume parameters.

Main Results:

• Current dose tolerance parameters for HGG are discussed in the context of varying patient populations and treatment regimens.
• Challenges in differentiating tumor effects from radiation-induced normal tissue damage are highlighted.
• Existing clinical trials addressing dose and volume parameters are reviewed.

Conclusions:

• Future HGG trials require prospective assessment of neurocognitive function and advanced imaging.
• This evaluation is crucial for predicting, preventing, and managing radiation-induced brain injury.
• Optimizing dose and volume parameters remains key for improving outcomes in HGG patients.